This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gerold Stucki, MD, MS
Zurich, Switzerland

Magnus Johannesson, PhD
Stockholm, Sweden

Matthew H. Liang, MD, MPH
Boston, Mass

Arch Intern Med. 1995;155(13):1451-1452.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In reply

We appreciate the comments of Fort and Hoffmann and Gabriel. Fort and Hoffmann state that misoprostol is indicated for nonsteroidal anti-inflammatory drug (NSAID) users with risk factors such as advanced age, history of peptic ulcer disease, and comorbid conditions, but its promotion and perceived indications are not as conservative. For instance, in the current issue of Drug Information for Physicians in Switzerland,¹ no mention of these risk factors is made.

The combination of misoprostol and a NSAID in fixed doses may increase compliance, but there are disadvantages as well. In patients with rheumatic diseases, the clinically effective dose and the time of administration for NSAIDs vary. With the use of fixed combinations, the effective and minimally necessary dose cannot be adjusted with the same caution as with single drugs. Our review was not about the rational use of misoprostol; it was about the evidence with regard to . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?